Back

ImmuneOnco Biopharmaceuticals-B subsidiary completes 50 million yuan capital increase

Verifying
  • ImmuneOnco Biopharmaceutical Technology completed its capital increase and related registration procedures.
  • Investors paid 50 million yuan, described as approximately $7.5 in the announcement.
  • ImmuneOnco Biopharmaceuticals-B identified the Shanghai company as its subsidiary.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
ImmuneOnco Biopharmaceuticals-B subsidiary completes 50 million yuan capital increase - CoinPost Terminal